These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10864101)

  • 21. Apparent insensitivity of the hotplate latency test for detection of antinociception following intraperitoneal, intravenous or intracerebroventricular M6G administration to rats.
    South SM; Smith MT
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1326-32. PubMed ID: 9732396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphine-3-glucuronide inhibits morphine induced, but enhances morphine-6-glucuronide induced locomotor activity in mice.
    Handal M; Ripel A; Aasmundstad T; Skurtveit S; Mørland J
    Pharmacol Biochem Behav; 2007 Mar; 86(3):576-86. PubMed ID: 17343905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morphine-6beta-glucuronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans.
    van Dorp EL; Kest B; Kowalczyk WJ; Morariu AM; Waxman AR; Arout CA; Dahan A; Sarton EY
    Anesthesiology; 2009 Jun; 110(6):1356-63. PubMed ID: 19461298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
    Wolff T; Samuelsson H; Hedner T
    Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphine glucuronidation increases its analgesic effect in guinea pigs.
    Oliveira A; Pinho D; Albino-Teixeira A; Medeiros R; Dinis-Oliveira RJ; Carvalho F
    Life Sci; 2014 Jul; 109(2):104-10. PubMed ID: 24968302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of metabolic effects of morphine-6-glucuronide by morphine-3-glucuronide.
    Hashiguchi Y; Molina PE; Abumrad NN
    Brain Res Bull; 1995; 38(4):325-9. PubMed ID: 8535854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.
    Zelcer N; van de Wetering K; Hillebrand M; Sarton E; Kuil A; Wielinga PR; Tephly T; Dahan A; Beijnen JH; Borst P
    Proc Natl Acad Sci U S A; 2005 May; 102(20):7274-9. PubMed ID: 15886284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.
    Romberg R; Olofsen E; Sarton E; den Hartigh J; Taschner PE; Dahan A
    Anesthesiology; 2004 Jan; 100(1):120-33. PubMed ID: 14695733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conditioned place preference induced by morphine and morphine-6-glucuronide in mice.
    Vindenes V; Handal M; Ripel A; Boix F; Mørland J
    Pharmacol Biochem Behav; 2006 Oct; 85(2):292-7. PubMed ID: 17011617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homozygous disruption of the mdrla P-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs.
    Saito T; Zhang ZJ; Ohtsubo T; Noda I; Shibamori Y; Yamamoto T; Saito H
    Acta Otolaryngol; 2001 Sep; 121(6):735-42. PubMed ID: 11678173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients.
    Ashby M; Fleming B; Wood M; Somogyi A
    J Pain Symptom Manage; 1997 Sep; 14(3):157-67. PubMed ID: 9291702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats.
    Lötsch J; Schmidt R; Vetter G; Schmidt H; Skarke C; Niederberger E; Geisslinger G; Tegeder I
    Neurosci Lett; 2002 Aug; 329(2):145-8. PubMed ID: 12165398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers.
    Lötsch J; Skarke C; Schmidt H; Grösch S; Geisslinger G
    Anesthesiology; 2001 Dec; 95(6):1329-38. PubMed ID: 11748388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat.
    Smith GD; Smith MT
    Pain; 1995 Jul; 62(1):51-60. PubMed ID: 7478708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High levels of morphine-6-glucuronide in street heroin addicts.
    Antonilli L; Semeraro F; Suriano C; Signore L; Nencini P
    Psychopharmacology (Berl); 2003 Nov; 170(2):200-4. PubMed ID: 12774191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the discriminative and antinociceptive effects of morphine and its glucuronide metabolites after central or systemic administration in the rat.
    Easterling KW; Holtzman SG
    Psychopharmacology (Berl); 1998 Nov; 140(1):91-7. PubMed ID: 9862407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
    Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
    Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions.
    Barrett DA; Barker DP; Rutter N; Pawula M; Shaw PN
    Br J Clin Pharmacol; 1996 Jun; 41(6):531-7. PubMed ID: 8799518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice.
    Kalvass JC; Graff CL; Pollack GM
    Pharm Res; 2004 Oct; 21(10):1867-70. PubMed ID: 15553234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
    Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
    Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.